<http://webisa.webdatacommons.org/9300182>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/prov#Entity> .
<http://webisa.webdatacommons.org/9300182>	<http://www.w3.org/ns/prov#wasQuotedFrom>	<biospace.com> .
<http://webisa.webdatacommons.org/prov/143992168>	<http://www.w3.org/ns/prov#wasDerivedFrom>	<http://webisa.webdatacommons.org/9300182> .
<http://webisa.webdatacommons.org/9300182>	<http://www.w3.org/ns/prov#value>	"In addition, the company also acquired intellectual property rights including issued and pending patent applications that augment the current patent estate protecting OTO-311.Emerging clinical data combined with completion of this transaction help set the stage for a streamlined development path for OTO-311 as a treatment for tinnitus, said David A. Weber, Ph.D., president and CEO of Otonomy." .